Are there clinically meaningful differences between vaccines against COVID-19? Global issues

We are thrilled to have you on our site. If you enjoy the post you have just found kindly Share it with friends.

A health worker prepares to administer the COVID-19 vaccine to a colleague at a hospital in Mogadishu, Somalia, in a May 24 video message to the World Health Assembly, the decision-making body of the United Nations agency Who is theUnited Nations Secretary-General António Guterres warned of the dangers.Two-speed global responseHe said, “Unfortunately, unless we act now, we are facing a situation in which rich countries impregnate the majority of their people and open up their economies, while the virus continues to cause profound suffering through rotation and transformation in the poorest countries.” UNICEF / Ismail Takasta
  • Opinion By Sunil J. Wimalawansa (New Jersey, USA)
  • Inter Press service

There are no statistically significant differences in efficacy between individual vaccines for different types: mRNA vaccines (eg, Pfizer and Moderna), Adenovirus vector vaccines (For example, AZN, J&J, and Sputnik V), Inactivated SARS-CoV-2 Vaccines (Eg, Sinovac and Valneva) in preventing severe complications and deaths.

If there is no contraindication indication, cause, or underlying belief not to be vaccinated, given the urgency of being vaccinated, individuals should take the vaccine provided to them.

The effectiveness of COVID vaccines:

According to global data, complications associated with COVID-19 among the adult population requiring hospital treatment are around 14%. According to the definition of hospitalization and mortality prevention, the reported efficacy of mRNA vaccines is approximately 94%.

Therefore, the average effectiveness of all COVID vaccines is around 90% (0.86 / 0.94 x 100). However, none of these vaccines completely prevent infection, transmission, permanent damage, or death.

The complication rate can be greatly reduced Pre-injury vitamin D supplementation or At the time of hospitalization (Mercola 2020; Wimalawansa, 2020) Concentration].

Most hospitalized COVID-19 patients have 25 (OH) D less than 20 ng / mL, while the vast majority of those who have died of COVID have levels below 10 ng / mL. It is noteworthy that more than 50 ng / mL is required for the proper operation of autocrine (inside each cell) and paracrine (adjacent cells) for signaling and immune cell functions.

These are required for rapid and well-regulated immune responses to combat pathogens. In absence, people develop complications.

Types of SARS-CoV-2 Vaccines:

MRNA vaccines for other diseases have not been published to humans outside of clinical trials. SARS-CoV-2 produces intense immune responses because the insertion processes within fine lipid particles allow the generation of large amounts of a portion of the viral prickly protein. It attacks the human immune system and eliminates these foreign proteins.

Spike proteins have a great affinity for ACE2 receptor protein It is located on the membranes of human epithelial cells in the lungs, gastrointestinal tract, blood vessels, etc. due to the similarity of the sequence of ACE-2 and ACE2-SARS.CoV-2 Complexes, the antibodies generated against spike proteins can damage normal cells in the presence of an incompetent immune system.

Why do some complications develop and others not?

After normal infection and vaccination, different types of antibodies are produced by immune cells. Some of these can interact with the ACE 2 receptor protein. Vitamin D is necessary for the proper functioning of the immune system. Vitamin D deficiency impairs innate and adaptive responses and allows hyperinflammation (Cell stormResponses.

Therefore, people with weakened immune systems have a higher risk of cross-reacting to the antigen, generating autoimmune reactions, and forming autoantibodies, which increases the risk of complications from SARS.

Inactivated viral vaccines are less used in western countries, despite the advantages of generating broader immune responses against nucleocapsid protein and spike protein. In contrast, the mRNA vaccine and the adenovirus vector vaccine only present a portion of the SPA of the immune system.

Therefore, the antibodies generated by mRNA vaccines have narrow specificity, which in the long term may be a defect.

The effectiveness of vaccine groups cannot be compared:

The conditions and timing of the vaccine trials that were conducted were significantly different. No face-to-face randomized controlled trials to compare mRNA vaccines or adenovirus vector vaccine with conventional inactivated viral vaccines, the safety of which is better understood.

The intense promotion, particularly by major investors and governments, of mRNA companies and virus vector vaccines is driven by higher patent-based profits for new mechanisms. Despite claims by companies, critics and the media, it cannot be assumed that the effectiveness of mRNA and virus vector vaccines is superior to conventional inactivated virus vaccines.

Randomized controlled trials of vaccines were conducted under different conditions:

Obtaining approval for mRNA vaccines for RCTs and EUA was clear. These randomized controlled trials (RCTs) were conducted in the USA during the summer and fall of 2020, prior to the emergence of COVID-19 variants. A few of these variants have evolved mutant proteins with much greater affinity for the ACE2 receptor to facilitate their entry into our cells.

As the vaccination program expands, variants continue to evolve, including dual (eg, Indian variant) and multiple mutations to evade immunity. Mutations generate different sequences of spike proteins (a) to overcome the recognition of antibodies and killer cells, and (b) to increase infection. The risks of such mutations are higher after mRNA vaccines and virus vectors.

The mRNA vaccine trials during the summer and fall included people with higher concentrations of vitamin D with less severe symptoms. In contrast, vector vaccines and inactivated viral vaccines took longer to obtain EUAs due to the complications requiring multiple approvals.

These randomized controlled trials were conducted primarily outside of the United States during the fall and winter seasons, after multiple variants emerged and when the spread of COVID-19 rose again.

Effectiveness versus adverse effects of vaccines:

There is no doubt about the benefits of COVID vaccines in adults. Given the different nature of randomized controlled trials and rapid deployments, there is insufficient comparable data to conclude that one vaccine is more effective than another.

Besides, incomplete reports and analyzes of negative interactions are a concern, especially the potential long-term adverse effects. For those who have a mild to moderate risk of contracting the harm from COVID-19, such as children, these poorly described risks should be considered more precisely in the context of the limited individual benefits of vaccination.

The ill effects of vaccines are the subject of ongoing research and debate, and therefore dialogue with freedom of expression should be permitted. Instead, such discussions are being suppressed and defamed: Officials are removing posts from social media sites under the pretext of reducing public confidence in COVID-19 vaccines.

People must be provided with the facts: they have the right to know the pros and cons and make their own decisions. In addition to Vitamin D deficiency, Emerging data indicate that the adverse effects are specific to a particular vaccine group, and possibly underlying vulnerability and individual characteristics, such as gender and age.

Vaccine uncertainty and duration of effectiveness:

Despite unfounded assertions by vaccine manufacturers and some administrative officials in top positions, claims of up to five years of post-vaccination immunity are speculation.

Duration of immunity from natural infection and COVID vaccines is uncertain. However, by extrapolating from SARS experience, post-vaccination immunity It may not last more than 18 months, which will hinder the development of global herd immunity.

Adequate vitamin D enhances the benefits of vaccines:

The most beneficial aspect of vaccinations is Adequacy of vitamin D. It prevents hospitalization, complications requiring oxygen and intensive care unit use, and deaths. Therefore, as with adequate vitamin D, vaccinations should also prevent post-COVID syndrome, also known as “ long COVID, ” which is a misnomer.

Post-COVID-19 syndrome mainly appears in the central nervous system or other places where SARS-CoV-2 can escape incomplete immune responses, especially in those areas. With severe vitamin D deficiency Hence, having a less powerful immune system.

Adequate vitamin D prevents post-COVID syndrome. It remains to be seen whether vaccines prevent post-COVID-19 syndrome, but she is optimistic.

Sunil J. Wimalawansa, MD, PhD, MBA, MD of Science, Professor of Medicine, Endocrinology and Nutrition, Director of the Heart and Metabolism Institute, USA[email protected]

Follow IPSNewsUNBureau
Follow the new IPS UN office on Instagram

© Inter Press Service (2021) – All rights reservedOriginal source: Inter Press Service


Disclaimer: The opinions expressed within this article are the personal opinions of the author. The facts and opinions appearing in the article do not reflect the views of and does not assume any responsibility or liability for the same.

Leave a Reply

Your email address will not be published. Required fields are marked *